Literature DB >> 2842362

Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man.

F Cuttitta1, J Fedorko, J A Gu, A M Lebacq-Verheyden, R I Linnoila, J F Battey.   

Abstract

Mammalian gastrin-releasing peptide (GRP) is found in cells of neuroendocrine and neural origin, and GRP mediates a variety of physiological and trophic responses when it binds to high affinity cell surface receptors on effector cells. Analysis of cDNA clones derived from prepro-GRP mRNAs predict the concurrent expression of a unique series of peptide hormones, the GRP gene-associated peptides (GGAPs). Alternative RNA splicing of the primary GRP gene transcript results in mRNAs that could encode 3 distinct forms of GGAPs. Using specific antisera directed against synthetic peptides representing portions of the predicted GGAPs, we found multiple GGAP forms in the endocrine cells of human fetal lung and in human small cell lung cancer cells (SCLC). Within a single pulmonary endocrine cell, at least 2 of these 3 predicted forms could be demonstrated using immunohistochemical techniques. In addition, concordant expression of GRP and GGAPs was found in 10 SCLC cell lines and 3 human SCLC tumors. These findings establish GGAPs as a novel peptide family in man and warrant further investigation into their potential role in normal and malignant growth.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842362     DOI: 10.1210/jcem-67-3-576

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Gastrin-releasing peptide in human nasal mucosa.

Authors:  J N Baraniuk; J D Lundgren; J Goff; D Peden; M Merida; J Shelhamer; M Kaliner
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 2.  SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases.

Authors:  Luis Michel Alonso Martinez; François Harel; Myriam Létourneau; Vincent Finnerty; Alain Fournier; Jocelyn Dupuis; Jean N DaSilva
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

Review 3.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

4.  v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line.

Authors:  J P Falco; S B Baylin; R Lupu; M Borges; B D Nelkin; R K Jasti; N E Davidson; M Mabry
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone.

Authors:  J M Siegfried; P G Kasprzyk; A M Treston; J L Mulshine; K A Quinn; F Cuttitta
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

6.  Pulmonary Neuroendocrine Cells and Lung Development.

Authors:  Mary E. Sunday
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

Review 7.  Autocrine growth factors and solid tumor malignancy.

Authors:  J H Walsh; W E Karnes; F Cuttitta; A Walker
Journal:  West J Med       Date:  1991-08

Review 8.  Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.

Authors:  Ewa Wojcik; Jan Kanty Kulpa
Journal:  Lung Cancer (Auckl)       Date:  2017-11-28

9.  p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

Authors:  T Unger; M M Nau; S Segal; J D Minna
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

10.  Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.

Authors:  M Takada; Y Kusunoki; N Masuda; K Matui; T Yana; S Ushijima; K Iida; K Tamura; T Komiya; I Kawase; N Kikui; H Morino; M Fukuoka
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.